Malignant neoplasm of male breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Male BC is almost exclusively hormone receptor positive (+), including the androgen receptor (AR), and is associated with an increased prevalence of BRCA2 germline mutations, especially in men with increased risk for developing high-risk BC.
|
30267249 |
2019 |
Malignant neoplasm of male breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Durable Response of Androgen Receptor-Positive Male Breast Cancer to Goserelin.
|
30941241 |
2019 |
Malignant neoplasm of male breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Not only the estrogen receptor (ER), but also other steroid hormone receptors, including the androgen receptor (AR) and progesterone receptor (PgR) are expressed in MBC.
|
30577860 |
2018 |
Malignant neoplasm of male breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Body mass index (P = .023) and DACH1 (P = .034) were correlated with MBC prognosis, whereas the expression of AR (P = .049), SIX1 (P = .048), surgery (P < .001), and chemotherapy (P = .001) were important for FBC in addition to already known factors: tumor size and location, TNM stage (lymph nodes and organ metastasis), radiotherapy, and ER and human epidermalgrowth factor receptor-2 (HER2) expression.
|
29478945 |
2018 |
Malignant neoplasm of male breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to investigate the role of the X chromosome gain in the development of MBC and its relation with AR gene copy number and expression.The X chromosome status was assessed in 66 cases of male invasive and in situ duct breast carcinoma, in 34 cases of gynecomastia associated with cancer, and in 11 cases of tumor-free gynecomastia.
|
29802469 |
2018 |
Malignant neoplasm of male breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This review critically discusses the recent developments in the study of male breast cancer in relation to ERα and AR action and highlights the potential future studies to further elucidate the genomic regulation of this rare disease.
|
28062545 |
2017 |
Malignant neoplasm of male breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Androgen receptor and antiandrogen therapy in male breast cancer.
|
26276719 |
2015 |
Malignant neoplasm of male breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, an analysis of genes correlated to steroid receptors and ERBB2 suggested a prominent role for the androgen receptor in MBC with a minor relevance for progesterone receptor and ERBB2, although, similarly to FBC, a genomic amplification could be observed.
|
20625818 |
2011 |
Malignant neoplasm of male breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study aimed to investigate for the first time the distribution of AR QT lengths among MBC patients in Egypt.
|
21505847 |
2011 |
Malignant neoplasm of male breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Forty one male breast cancer samples were studied, including one sample from a man with spinal and bulbar muscular atrophy (SBMA), which is caused by an AR CAG repeat expansion.
|
15609126 |
2004 |
Malignant neoplasm of male breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients.
|
14555518 |
2003 |
Malignant neoplasm of male breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our data indicate that the AR gene does not substantially contribute to MBC predisposition.
|
12602915 |
2003 |
Malignant neoplasm of male breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The entire coding region of the BRCA2 gene and two exons of the AR gene were analyzed for germ-line mutations to evaluate the association between BRCA2 and AR genes and male breast cancer in Poland.
|
11139248 |
2001 |
Malignant neoplasm of male breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Some AR ZFR point mutations observed in patients with partial androgen insensitivity syndrome or male breast cancer impair the interaction of AR with SNURF and also render AR refractory to the transcription-activating effect of SNURF.
|
10617653 |
2000 |
Malignant neoplasm of male breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Arg607-Gln and Arg608-Lys point mutations in the DNA-binding domain of the AR gene have been associated with male breast cancer in partial androgen insensitivity syndrome.
|
10221692 |
1999 |
Malignant neoplasm of male breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Two heritable gene defects have been associated with a predisposition to male breast cancer development, ie., germ-line mutations in the breast cancer susceptibility gene BRCA2 and the androgen receptor (AR) gene.
|
9537231 |
1998 |
Malignant neoplasm of male breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Functional and structural analysis of R607Q and R608K androgen receptor substitutions associated with male breast cancer.
|
9220020 |
1997 |
Malignant neoplasm of male breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results indicate that somatic mutations of the androgen receptor are not required for the development of male breast cancer.
|
8784104 |
1996 |
Malignant neoplasm of male breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Similarly, in the two cases of male breast cancer in which AR gene mutations have been described, the mutations in the DNA binding domain of the receptor are alike.
|
7489816 |
1995 |
Malignant neoplasm of male breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Moreover, androgen receptor gene alterations have been recently described in two unrelated diseases: male breast cancer and spinal and bulbar muscular atrophy.
|
7920176 |
1994 |
Malignant neoplasm of male breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This androgen receptor mutation along with the Arg608 into Lys mutation we describe, suggests that this genetic abnormality is not fortuitous: a decrease in androgen action within the breast cells could account for the development of male breast cancer by the loss of a protective effect of androgens on these cells.
|
8281139 |
1993 |